Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

re reduced or delayed. The primary and secondary endpoints of the denosumab bone metastases studies use a composite endpoint of four SREs - fracture, the need for radiation to bone, the need for bone surgery, and spinal cord compression - to measure the effectiveness of denosumab versus Zometa.

The primary endpoint was to evaluate if denosumab is non-inferior to Zometa with respect to the first on-study SRE in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma and bone metastases. Secondary endpoints were to evaluate if denosumab is superior to Zometa with respect to the first on-study SRE, as well as first-and-subsequent on-study SREs, and to assess the safety and tolerability of denosumab compared with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer-induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials, testing the drug for the reduction of SREs in breast cancer patients, for the amelioration of treatment-induced bone loss in patients with breast or prostate cancers, for the prevention of SREs due to the spread of cancer to the bone in patients with multiple myeloma or those suffering from a variety of solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Pre
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Diseases largely eradicated in the United States ... declared eliminated in 2000, yet the CDC reports 593 ... incidence in 20 years. In July, California,s ... problem of "epidemic proportions." Across ... preventable diseases—in part because some parents (more than 10 ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... June 2 The United States Court of Appeals ... lawsuit brought by Haemonetics Corporation against Fenwal and Baxter Healthcare Corporation in 2005, ... Court for Massachusetts verdict against Fenwal as well as the related ... , In its ...
... , PITTSBURGH , June 2 At a time ... study from Highmark Inc. has revealed that the integration of medical and ... , , ... on health benefits costs, some employers choose a "carve-out" model by contracting ...
Cached Medicine Technology:Appellate Court Decides in Favor of Fenwal 2Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health 2Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health 3
(Date:8/29/2014)... (PRWEB) August 29, 2014 ReputationChief.Com, a ... service named ‘Remove Bad Reviews’. This service has been ... on account of negative reviews against them. , In ... fail to deliver the committed results to its clients, ... about the world of internet marketing. , As per ...
(Date:8/29/2014)... 29, 2014 Senior Independence ... & business development. , Rees has been with Senior ... business development. , A wholly owned subsidiary of ... older adults with options, including personalized home health care ... meal preparation) and therapeutic adult day centers. , Rees ...
(Date:8/29/2014)... 2014 RBS Reputation Management has brought a ... The service is to help those individuals and organizations that ... Scam Book. The service would push down the ranking of ... complaints fully invisible on Google. , RBS Reputation Management ... being asked how company can provide guarantee of results with ...
(Date:8/29/2014)... University of Houston Graduate College of Social Work is the ... million grant from the National Institute of Drug Abuse (NIDA) ... long-term use and health consequences of heroin use. Additionally, the ... future research endeavors. , Heroin use has increased ... prescription pain medication abuse to the cheaper and more available ...
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... DDS, is now offering mini implants to area patients. ... permanently without worries of long-term teeth shifting and loss ... associated with full-size dental implants , their smaller ... as faster placement and easier recovery. Once placed, mini ...
Breaking Medicine News(10 mins):Health News:ReputationChief.Com Announces a New Service ‘Remove Bad Reviews’ 2Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2
... Texas, Nov. 11 Wound Management Technologies, Inc., ... Division will search for partners to aid in ... opportunities within the International Biotechnology and Genetic Engineering ... advisory board appointments, research affiliations, and new partners ...
... the University of Leeds have developed a simple technology ... ensure "right first time" drug crystal formation. Ensuring ... efficacy and the efficiency of pharmaceutical manufacturers, operations. Using ... that crystals form into their desired product form with ...
... or catheter-directed thrombolysisan interventional radiology treatment that uses ... to dissolve dangerous blood clots in the lungssaves ... option for massive pulmonary embolism, note researchers in ... Radiology . "Modern catheter-directed therapy for ...
... ... with the new Advice on Hearing Aids website. , ... (PRWEB) November 11, 2009 -- AdviceOnHearingAids.com, a national ... resource for doctors and professionals in the hearing aid business. Already considered an ...
... ... and the New Economy as kickoff for their new website and the Performance Connections ... ... pressing in business than the financial health of a commercial enterprise. The two primary ...
... hazards from the plastics chemical , WEDNESDAY, Nov. 11 ... controversial plastics chemical bisphenol A (BPA) significantly raised the ... drive, among Chinese factory workers, a new study has ... were exposed to BPA levels about 50 times higher ...
Cached Medicine News:Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 2Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 3Health News:Right first time: Pioneering new methods of drug manufacture 2Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 2Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 3Health News:Online Hearing Aid Information Website Redefines Hearing Aid Marketing 2Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 2Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 3Health News:BPA Tied to Impotence in Men 2Health News:BPA Tied to Impotence in Men 3
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
... eye. Laser resistant foam surrounds the lower 17cm ... other) 40cm (16") long, Single Use. The tracheal ... optimum visibility within the operating site, while maintaining ... laser-guard of approx. 17cm in length proximal to ...
Medicine Products: